Business Description
Myriad Genetics Inc
NAICS : 325413
SIC : 2835
ISIN : US62855J1043
Share Class Description:
MYGN: Ordinary SharesTotal Employee Number:
2,700Description
Myriad Genetics Inc. is a US-based molecular diagnostics company that develops and commercializes genetic and genomic tests used across oncology, women's health, and mental health. Its portfolio includes hereditary cancer risk tests such as MyRisk and BRACAnalysis, tumor profiling and companion diagnostics including MyChoice CDx and Precise Tumor, the Prolaris prostate cancer test, the GeneSight pharmacogenomic test for depression and other psychiatric conditions, and the SneakPeek early fetal sex determination test. These tests are ordered by physicians, hospitals, health systems, and payers, and are used to assess disease risk, guide treatment selection, and inform reproductive decisions. Myriad generates revenue primarily through third-party reimbursement from insurers and government payers, along with direct patient billing. The company operates mainly in the United States, which accounts for the large majority of its revenue, and also sells in selected international markets.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.55 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | -4.66 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -0.98 | |||||
Beneish M-Score | -3.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.9 | |||||
3-Year EBITDA Growth Rate | -50.4 | |||||
3-Year FCF Growth Rate | 47.3 | |||||
3-Year Book Growth Rate | -28.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.88 | |||||
9-Day RSI | 68.61 | |||||
14-Day RSI | 61.41 | |||||
3-1 Month Momentum % | -36.78 | |||||
6-1 Month Momentum % | -38.15 | |||||
12-1 Month Momentum % | -62.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.21 | |||||
Quick Ratio | 1.98 | |||||
Cash Ratio | 0.88 | |||||
Days Inventory | 43.38 | |||||
Days Sales Outstanding | 54.63 | |||||
Days Payable | 45.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -19.02 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.83 | |||||
Operating Margin % | -11.22 | |||||
Net Margin % | -13.96 | |||||
EBITDA Margin % | -5.6 | |||||
FCF Margin % | -0.91 | |||||
OCF Margin % | 0.95 | |||||
ROE % | -31.8 | |||||
ROA % | -16.44 | |||||
ROIC % | -18.83 | |||||
3-Year ROIIC % | -6.87 | |||||
ROC (Joel Greenblatt) % | -42.57 | |||||
ROCE % | -17.79 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 83.5 | |||||
PS Ratio | 0.36 | |||||
PB Ratio | 1.26 | |||||
Price-to-Tangible-Book | 3.26 | |||||
Price-to-Operating-Cash-Flow | 47.78 | |||||
EV-to-EBIT | -5.01 | |||||
EV-to-Forward-EBIT | 72.31 | |||||
EV-to-EBITDA | -10.33 | |||||
EV-to-Forward-EBITDA | 14.95 | |||||
EV-to-Revenue | 0.59 | |||||
EV-to-Forward-Revenue | 0.59 | |||||
EV-to-FCF | -65.53 | |||||
Price-to-GF-Value | 0.35 | |||||
Price-to-Median-PS-Value | 0.2 | |||||
Earnings Yield (Greenblatt) % | -19.96 | |||||
FCF Yield % | -1.9 | |||||
Forward Rate of Return (Yacktman) % | 26.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MYGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Myriad Genetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 806.6 | ||
| EPS (TTM) ($) | -1.199 | ||
| Beta | 1.2161 | ||
| 3-Year Sharpe Ratio | -0.41 | ||
| 3-Year Sortino Ratio | -0.58 | ||
| Volatility % | 79.38 | ||
| 14-Day RSI | 61.41 | ||
| 14-Day ATR ($) | 0.250747 | ||
| 20-Day SMA ($) | 3.4235 | ||
| 12-1 Month Momentum % | -62.63 | ||
| 52-Week Range ($) | 2.74 - 8.59 | ||
| Shares Outstanding (Mil) | 95.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Myriad Genetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Myriad Genetics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-24 | In 155 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-23 16:30 | In 155 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-23 | In 154 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 43 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 42 days | ||
| 21(st) Annual Wells Fargo Healthcare Conference | 2026-09-10 11:00 | 3.19 (+2.57%) | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 16:30 | 5.04 (-5.44%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 5.04 (-5.44%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 08:40 | 4.54 (+2.71%) | ||
| General meeting for 2026 | 2026-06-04 08:00 | 4.40 (+2.80%) |
Show
Entries
Myriad Genetics Inc Frequently Asked Questions
What is Myriad Genetics Inc(MYGN)'s stock price today?
The current price of MYGN is $4.01. The 52 week high of MYGN is $8.59 and 52 week low is $2.74.
When is next earnings date of Myriad Genetics Inc(MYGN)?
The next earnings date of Myriad Genetics Inc(MYGN) is 2026-11-03 Est..
Does Myriad Genetics Inc(MYGN) pay dividends? If so, how much?
Myriad Genetics Inc(MYGN) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers